AB0464 DRUG SURVIVAL OF TNFi AND SECUKINUMAB IN AXIAL SPONDYLARTHRITIS: A REAL-WORLD MULTICENTRIC COHORT OF 370 PATIENTS

Background: IL17 inhibitors (IL17i) are an alternative for patients with axial spondyloarthritis (axSpA) who did not respond to TNF (TNFi). Secukinumab (SEC) is the first human monoclonal antibody that binds protein interleukin-17A. Objectives: The objectives of this study were describe characteristics axSpA treated IL17i and TNFi assess persistence in a real world cohort. Methods: A retrospective multicenter observational was conducted. (pts) according ASAS criteria initiating or between June 2016 December 2019 included. Demographic features, current previous use biologic Disease-modifying antirheumatic drugs (bDMARDs) collected. Date reasons discontinuation – i.e., lack efficacy, safety issue, sustained remission others Kaplan-Meyer analysis performed. Results: 370 pts Among 202 received TNFi, 90 (44.6%) female, mean age 43.2 +/- 13.2 years, body mass index 26.1 kg/m 2 5.4, 49 (46.7%) smokers. most common SpA phenotype radiographic (n = 89, 54,9%) 114 (68.3%) HLA B27 positive, BASDAI 57.5 14.6, median disease duration 8.6 years [3.0-10.5]. 168 SEC, 78 (46.4%) 47.7 11.8 27.2 5.8, 45 (44.1%) 106, 76,3%) (78.1%) 62.8 14.8, 9 [5.0-19.0]. line bDMARD 116/202 (57.4%) SEC 15/168 (8.9%). prescribed at 150mg every month 121/168 (73.3%) pts. 18.0 months [11.0-27.0] 12.0 [6.0-22.0], respectively. During 3-year follow-up, 130 (42 88 SEC) discontinued treatment: 80 (22 58 effectiveness, 41 (16 25 adverse events. No patient presented new-onset inflammatory bowel disease. Figure 1. Persistence after 3 follow-up Conclusion: In cohort AxSpA pts, mostly second third-line, contrary TNFi. Most reason related effectiveness both therapeutic classes. Disclosure Interests: Thibaut DELEPINE: None declared., Peggy Philippe Speakers bureau: Abbvie, MSD, Fresenius, Pfizer, UCB Pharma, Novartis, Consultant of: Emeline Cailliau: Eric Houvenagel: Xavier Deprez UCB, René-Marc Flipo Lilly, Jean-Guillaume Letarouilly Grant/research support from: Pfizer (research grant).